Cargando…
Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure
Patients with type 2 diabetes mellitus are at a higher risk of developing heart failure compared with the healthy population. In recent landmark clinical trials, sodium-glucose co-transporter 2 (SGLT2) inhibitor therapies improve blood glucose control and also reduce cardiovascular events and heart...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8223636/ https://www.ncbi.nlm.nih.gov/pubmed/33637556 http://dx.doi.org/10.1136/heartjnl-2020-318060 |